Evidence map›Paper›PMID 40756506›Full record

ReviewFrontiers in endocrinology2025

Advances in

Yuliya Kupriyanova, Vera Schrauwen-Hinderling

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yuliya KupriyanovaInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Vera Schrauwen-HinderlingInstitute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Magnetic Resonance Spectroscopy (MRS) and Magnetic Resonance Imaging (MRI) yield valuable metabolic information in a non-invasive way. The current mini review addresses current practice and recent advances in metabolic research, specifically in the field of obesity, insulin resistance and diabetes. The potential application of MRS to investigate lipid and glycogen stores, as well as energy metabolism are reviewed and novel methods to extract more detailed information on fatty acid composition or newly detectable metabolites such as acetylcarnitine or nicotinamide adenosine dinucleotide (NAD

Indexed as

Metabolic DiseasesAnimalsEnergy MetabolismHumansMagnetic Resonance ImagingMagnetic Resonance Spectroscopydiabetesglycogenlipid metabolismmagnetic resonance spectroscopymetabolic healthmitochondrial function

Identifiers

PMID40756506
PMCPMC12313504

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.